Document is current
Any future updates will be listed below
-
Authors
Zhang, Guanglan http://orcid.org/0000-0001-6010-490X
Chitkushev, Lou
Olsen, Lars Rønn
Keskin, Derin B.
Brusic, Vladimir
-
Funding
Funding for this research was provided by:
National Cancer Institute (NCI-SPORE-2P50CA101942-11A1)
Division of Cancer Epidemiology and Genetics, National Cancer Institute (R21 CA216772-01A1)
- License Information
-
More Information
Article History
Received: 6 January 2021
Accepted: 8 January 2021
First Online: 14 April 2021
Ethics approval and consent to participate
: No ethics approval was required for the study.
: Not applicable.
: DBK has previously advised and received consulting fees from Neon Therapeutics. DBK and GLZ own equity in Aduro Biotech, Agenus Inc., Armata pharmaceuticals, Breakbio Corp., Biomarin Pharmaceutical Inc., Bristol Myers Squibb Com., Celldex Therapeutics Inc., Editas Medicine Inc., Exelixis Inc., Gilead Sciences Inc., IMV Inc., Lexicon Pharmaceuticals Inc., Moderna Inc., Regeneron Pharmaceuticals, and Stemline Therapeutics Inc.
